Current Report Filing (8-k)
November 08 2017 - 06:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported)
November 5,
2017
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
333-143570
|
36-4296006
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
4203 SW 34
th
St.
|
|
Orlando,
FL
|
32811
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
On
November 5, 2017, the Board of Directors (the “Board”)
of MEDITE Cancer Diagnostics, Inc. (the “Company”) held
a meeting whereby David E. Patterson informed the Board of his
decision to retire as Chief Executive Officer of the Company, and
resign his position as Chairman of the Board and Board member of
the Company, all effective immediately. M
r.
Patterson shall receive three (3) equal monthly payments with each
payment being equal to his monthly salary, and all future
restricted stock grants in the amount of 166,667 shares pursuant to
his employment agreement shall fully vest as of January 1, 2018,
and be issued in consideration for assisting the Company through a
transition period.
Thereafter,
Stephen Von Rump was appointed by a unanimous vote of the Board to
the position of Chief Executive Officer of the Company upon the
same terms and conditions as his current employment, to serve until
his resignation or removal.
The
Board thereafter, by unanimous consent, appointed current Board
member, William Austin Lewis IV, to the position of Chairman of the
Board of Directors of Company to serve until such time as his
removal or resignation.
Item
9.01
Financial Statements and Exhibits
Exhibit No
.
Description
Resignation Letter
of David E. Patterson
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
Date:
November 7, 2017
|
By:
|
/s/ Stephen Von Rump
|
|
|
Stephen
Von Rump
|
|
|
Chief
Executive Officer
|
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Mar 2023 to Mar 2024